MiR-193b directly targets STMN1 and uPA genes and suppresses tumor growth and metastasis in pancreatic cancer

Molecular Medicine Reports

Volumn 10, Issue 5, 2014, Pages 2613-2620

  Li, Jian ^a   Kong, Fujiao ^a   Wu, Kemin ^a   Song, Kun ^a   He, Jianfeng ^a   Sun, Weijia ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Metastasis; MiR 193b; Pancreatic cancer; STMN1; Tumor proliferation; UPA

Indexed keywords

ANTIMETASTATIC AGENT; MESSENGER RNA; MICRORNA; MICRORNA 193B; STATHMIN; STATHMIN 1; UNCLASSIFIED DRUG; UROKINASE; 3' UNTRANSLATED REGION; MIRN193 MICRORNA, HUMAN; STMN1 PROTEIN, HUMAN;

3' UNTRANSLATED REGION; ADULT; AGED; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BINDING SITE; CANCER GROWTH; CANCER INHIBITION; CANCER SIZE; CANCER STAGING; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION ASSAY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG PROTEIN BINDING; FEMALE; GENE REPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; METASTASIS INHIBITION; MIDDLE AGED; PANCREAS CANCER; PANCREATIC CANCER CELL LINE; PROTEIN EXPRESSION; TUMOR INVASION; CELL MOTION; CELL PROLIFERATION; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; METASTASIS; NUCLEOTIDE SEQUENCE; PANCREAS TUMOR; PATHOLOGY; TUMOR CELL LINE; TUMOR VOLUME;

3' UNTRANSLATED REGIONS; ADULT; AGED; APOPTOSIS; BASE SEQUENCE; BINDING SITES; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PANCREATIC NEOPLASMS; STATHMIN; TUMOR BURDEN; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 84907187933     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.2558     Document Type: Article

References (34)

1. Arora S, Bhardwaj A, Srivastava SK, Singh S, McClellan S, Wang B and Singh AP: Honokiol arrests cell cycle, induces apoptosis, and potentiates the cytotoxic effect of gemcitabine in human pancreatic cancer cells. PLoS One 6: e21573, 2011.
2. Niedergethmann M, Alves F, Neff JK, et al: Gene expression profiling of liver metastases and tumour invasion in pancreatic cancer using an orthotopic SCID mouse model. Br J Cancer 97: 1432-1440, 2007.
3. Garzon R, Calin GA and Croce CM: MicroRNAs in cancer. Annu Rev Med 60: 167-179, 2009.
4. Iorio MV and Croce CM: MicroRNAs in cancer: small molecules with a huge impact. J Clin Oncol 27: 5848-5856, 2009.
5. Croce CM and Calin GA: miRNAs, cancer, and stem cell division. Cell 122: 6-7, 2005.
6. Gregory RI and Shiekhattar R: MicroRNA biogenesis and cancer. Cancer Res 65: 3509-3512, 2005.
7. Shen J, Stass SA and Jiang F: MicroRNAs as potential biomarkers in human solid tumors. Cancer Lett 329: 125-136, 2013.
8. Nana Sinkam SP and Croce CM: Clinical applications for microRNAs in cancer. Clin Pharmacol Ther 93: 98-104, 2013.
9. Wu W, Lin Z, Zhuang Z and Liang X: Expression profile of mammalian microRNAs in endometrioid adenocarcinoma. Eur J Cancer Prev 18: 50-55, 2009.
10. Rauhala HE, Jalava SE, Isotalo J, et al: miR 193b is an epigenetically regulated putative tumor suppressor in prostate cancer. Int J Cancer 127: 1363-1372, 2010.
11. Xu C, Liu S, Fu H, et al: MicroRNA 193b regulates proliferation, migration and invasion in human hepatocellular carcinoma cells. Eur J Cancer 46: 2828-2836, 2010.
12. Li XF, Yan PJ and Shao ZM: Downregulation of miR 193b contributes to enhance urokinase type plasminogen activator (uPA) expression and tumor progression and invasion in human breast cancer. Oncogene 28: 3937-3948, 2009.
13. Hu H, Li S, Liu J and Ni B: MicroRNA 193b modulates proliferation, migration, and invasion of non small cell lung cancer cells. Acta Biochim Biophys Sin (Shanghai) 44: 424-430, 2012.
14. Ikeda Y, Tanji E, Makino N, Kawata S and Furukawa T: MicroRNAs associated with mitogen activated protein kinase in human pancreatic cancer. Mol Cancer Res 10: 259-269, 2012
15. Lewis BP, Shih IH, Jones Rhoades MW, Bartel DP, Burge CB. Prediction of mammalian microRNA targets. Cell 115:787-98, 2003.
16. Griffiths Jones S, Grocock RJ, van Dongen S, Bateman A, Enright AJ. MiR Base: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res 34:D140-D144, 2006.
17. Krek A, Grün D, Poy MN, Wolf R, Rosenberg L,Epstein EJ, MacMenamin P, da Piedade I, Gunsalus KC, Stoffel M, Rajewsky N. Combinatorial microRNA target predictions. Nat Genet 37:495-500, 2005.
18. Chen J, Zhang X, Lentz C, Abi Daoud M, Pare GC, Yang X, et al: miR 193b regulates mcl 1 in melanoma. Am J Pathol 176: 2162-2168, 2011.
19. Tahiri A, Leivonen SK, Lüders T, et al: Deregulation of cancer related miRNAs is a common event in both benign and malignant human breast tumors. Carcinogenesis 35: 76-85, 2014.
20. Zhou H, Wang K, Hu Z and Wen J: TGF β1 alters microRNA profile in human gastric cancer cells. Chin J Cancer Res 25: 102-111, 2013.
21. Cheung TH, Man KN, Yu MY, et al: Dysregulated microRNAs in the pathogenesis and progression of cervical neoplasm. Cell Cycle 11: 2876-2884, 2012.
22. Xie C, Jiang XH, Zhang JT, et al: CFTR suppresses tumor progression through miR 193b targeting urokinase plasminogen activator (uPA) in prostate cancer. Oncogene 32: 2282-2291, 2013.
23. Chen J, Feilotter HE, Pare GC, et al: MicroRNA 193b represses cell proliferation and regulates cyclin D1 in melanoma. Am J Pathol 176: 2520-2529, 2010.
24. Rana S, Maples PB, Senzer N and Nemunaitis J: Stathmin 1: A novel therapeutic target for anticancer activity. Expert Rev Anticancer Ther 8: 1461-1470, 2008.
25. Belletti B and Baldassarre G: Stathmin: A protein with many tasks. New biomarker and potential target in cancer. Expert Opin Ther Targets 15: 1249-1266, 2011.
26. Mistry SJ and Atweh GF: Role of stathmin in the regulation of the mitotic spindle: potential applications in cancer therapy. Mt Sinai J Med 69: 299-304, 2002.
27. Ke B, Wu LL, Liu N, Zhang RP, Wang CL and Liang H: Overexpression of stathmin 1 is associated with poor prognosis of patients with gastric cancer. Tumour Biol 34: 3137-3145, 2013.
28. Tamura K, Yoshie M, Miyajima E, Kano M and Tachikawa E: Stathmin regulates hypoxia inducible factor 1α expression through the mammalian target of rapamycin pathway in ovarian clear cell adenocarcinoma. ISRN Pharmacol: 279593, 2013. doi: 10.1155/2013/279593.
29. Jiang L, Chen Y, Chan CY, et al: Down regulation of stathmin is required for TGF beta inducible early gene 1 induced growth inhibition of pancreatic cancer cells. Cancer Lett 274: 101-108, 2009.
30. Wang Y, Kuramitsu Y, Ueno T, et al: Proteomic differential display identifies upregulated vinculin as a possible biomarker of pancreatic cancer. Oncol Rep 28: 1845-1850, 2012.
31. Reichel CA, Kanse SM and Krombach F: At the interface of fibrinolysis and inflammation: The role of urokinase type plasminogen activator in the leukocyte extravasation cascade. Trends Cardiovasc Med 22: 192-196, 2012.
32. Cantero D, Friess H, Deflorin J, et al: Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma. Br J Cancer 75: 388-395, 1997.
33. He X, Zheng Z, Li J, et al: DJ 1 promotes invasion and metastasis of pancreatic cancer cells by activating SRC/ERK/uPA. Carcinogenesis 33: 555-562, 2012.
34. Saldanha RG, Xu N, Molloy MP, Veal DA and Baker MS: Differential proteome expression associated with urokinase plasminogen activator receptor (uPAR) suppression in malignant epithelial cancer. J Proteome Res 7: 4792-4806, 2008.